Yumanity Therapeutics successfully completes its Phase 1b trial of YTX-7739

[jeffreyn]

"Yumanity Therapeutics announced that its investigational therapy, YTX-7739, worked to safely inhibit stearoyl-CoA desaturase — an enzyme thought to play a role in the alpha-synuclein-derived toxicity seen in Parkinson’s — in a Phase 1b clinical trial in people with mild-to-moderate disease."

parkinsonsnewstoday.com/202...

A Phase 2 trial could start sometime next year, and if successful, a Phase 3 trial could follow.

Once again, some good news, but don't hold your breath waiting for a drug to be available anytime soon.

[Hidden]

Yumanity @Yumanitytx

reports a partial clinical hold order from the

@US_FDA

on their multi-dose clinical trials for YTX-7739 - a stearoyl-CoA desaturase inhibitor being developed for #Parkinsons; Yumanity is allowed to conduct a planned single dose trial

globenewswire.com/news-rele...

[Hidden]

YTX-7739, shows dose-dependent decreases in brain FADI ~to plasma; supports plasma FADI as surrogate clinical development biomarker.

Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease

link.springer.com/article/1...